{"protocolSection": {"identificationModule": {"nctId": "NCT00528879", "orgStudyIdInfo": {"id": "MB102-014 LT"}, "secondaryIdInfos": [{"id": "MB102-014", "type": "OTHER", "domain": "Other Study ID Numbers:"}], "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone", "officialTitle": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone"}, "statusModule": {"statusVerifiedDate": "2015-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-09"}, "primaryCompletionDateStruct": {"date": "2008-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-09-11", "studyFirstSubmitQcDate": "2007-09-11", "studyFirstPostDateStruct": {"date": "2007-09-12", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2014-02-06", "resultsFirstSubmitQcDate": "2014-04-01", "resultsFirstPostDateStruct": {"date": "2014-05-02", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-09-30", "lastUpdatePostDateStruct": {"date": "2015-10-20", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}, "collaborators": [{"name": "Bristol-Myers Squibb", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this clinical research study is to learn whether dapagliflozin can help reduce blood sugar levels in participants with Type 2 diabetes that is not well controlled on metformin alone. The safety of this treatment will also be studied."}, "conditionsModule": {"conditions": ["Type 2 Diabetes"], "keywords": ["Diabetes Mellitus, Type 2", "Diabetes Mellitus", "Endocrine System Diseases", "Glucose Metabolism Disorders", "Metabolic Diseases", "Metformin", "Hypoglycemic Agents", "Pharmacologic Actions", "Physiological Effects of Drugs"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 915, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo + Metformin", "type": "PLACEBO_COMPARATOR", "description": "Participants received dapagliflozin-matching placebo once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks", "interventionNames": ["Drug: Placebo", "Drug: Metformin"]}, {"label": "Dapagliflozin, 2.5 mg + Metformin", "type": "EXPERIMENTAL", "description": "Participants received dapagliflozin, 2.5 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks", "interventionNames": ["Drug: Dapagliflozin", "Drug: Metformin"]}, {"label": "Dapagliflozin, 5 mg + Metformin", "type": "EXPERIMENTAL", "description": "Participants received dapagliflozin, 5 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks", "interventionNames": ["Drug: Dapagliflozin", "Drug: Metformin"]}, {"label": "Dapagliflozin, 10 mg + Metformin", "type": "EXPERIMENTAL", "description": "Participants received dapagliflozin, 10 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks", "interventionNames": ["Drug: Dapagliflozin", "Drug: Placebo", "Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "Dapagliflozin", "description": "Tablets administered orally as a 2.5-, 5-, or 10-mg dose once daily for up to 102 weeks", "armGroupLabels": ["Dapagliflozin, 10 mg + Metformin", "Dapagliflozin, 2.5 mg + Metformin", "Dapagliflozin, 5 mg + Metformin"], "otherNames": ["BMS-512148"]}, {"type": "DRUG", "name": "Placebo", "description": "Dapagliflozin-matching placebo administered as tablets orally once daily for up to 102 weeks", "armGroupLabels": ["Dapagliflozin, 10 mg + Metformin", "Placebo + Metformin"]}, {"type": "DRUG", "name": "Metformin", "description": "Open-label metformin administered as \u22651500 mg per day for up to 102 weeks", "armGroupLabels": ["Dapagliflozin, 10 mg + Metformin", "Dapagliflozin, 2.5 mg + Metformin", "Dapagliflozin, 5 mg + Metformin", "Placebo + Metformin"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF])", "description": "HbA1c was measured as percent of hemoglobin by a central laboratory. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. HbA1c measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 4, 8, 12, 16, 20, and 24 in the double-blind period.", "timeFrame": "From Baseline to Week 24"}], "secondaryOutcomes": [{"measure": "Adjusted Mean Change From Baseline in Fasting Plasma Glucose at Week 24 (Last Observation Carried Forward [LOCF])", "description": "Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Data after rescue medication was excluded from this analysis. Fasting plasma glucose was measured as milligrams per deciliter (mg/dL) by a central laboratory. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication.", "timeFrame": "From Baseline to Week 24"}, {"measure": "Adjusted Mean Change From Baseline in Total Body Weight at Week 24 (Last Observation Carried Forward [LOCF])", "description": "Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Adjusted mean change from baseline in total body weight at Week 24 (or the last postbaseline measurement prior to Week 24 if no Week 24 assessment was available was determined. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Body weight measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 of the double-blind period.", "timeFrame": "From Baseline to Week 24"}, {"measure": "Percentage of Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF])", "description": "Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Percent adjusted for baseline HbA1c. Therapeutic glycemic response is defined as HbA1c \\<7.0%. Data after rescue medication was excluded from this analysis. HbA1c was measured as a percent of hemoglobin.", "timeFrame": "From Baseline to Week 24"}, {"measure": "Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) in Participants With Baseline HbA1c \u22659.0% at Week 24 (Last Observation Carried Forward [LOCF])", "description": "Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. HbA1c was measured as percent of hemoglobin by a central laboratory. The population included those randomized participants who received treatment and had a baseline HbA1c \\> 9.0%. Data after rescue medication were excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication.", "timeFrame": "From Baseline to Week 24"}, {"measure": "Adjusted Mean Change From Baseline in Total Body Weight at Week 24 in Participants With Baseline Body Mass Index (BMI) \u226527 kg/m^2 (Last Observation Carried Forward [LOCF])", "description": "Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Adjusted mean change from baseline in total body weight at Week 24 (or the last postbaseline measurement prior to Week 24 if no Week 24 assessment was available was determined.) Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Body weight measurements were obtained during the qualification and lead-in Periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 of the double-blind period.", "timeFrame": "From Baseline to Week 24"}, {"measure": "Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) in Participants With Baseline Body Mass Index (BMI) \u226527 kg/m^2 at Week 24 (Last Observation Carried Forward [LOCF])", "description": "Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Adjusted for baseline HbA1c. HbA1c was measured as percent of hemoglobin by a central laboratory. Data after rescue medication were excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication.", "timeFrame": "From Baseline to Week 24"}, {"measure": "Adjusted Mean Change From Baseline in Fasting Plasma Glucose at Week 1 (Last Observation Carried Forward [LOCF])", "description": "Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Data after rescue medication was excluded from this analysis. Fasting plasma glucose was measured by a central laboratory. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication.", "timeFrame": "From Baseline to Week 1"}, {"measure": "Adjusted Percentage of Participants Achieving Hemoglobin A1c (HbA1C) \u22646.5% at Week 24 (Last Observation Carried Forward [LOCF])", "description": "Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Percent adjusted for baseline HbA1c. Data after rescue medication was excluded from this analysis. HbA1c was measured as a percent of hemoglobin.", "timeFrame": "From Baseline to Week 24"}], "otherOutcomes": [{"measure": "Number of Participants With Adverse Events (AEs), Hypoglycemia Events, Related AEs, Death as Outcome, Serious AEs (SAEs), Related SAEs, SAEs Leading to Discontinuation, AEs Leading to Discontinuation, and Hypoglycemia Events Leading to Discontinuation", "description": "AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Related=having certain, probable, possible, or missing relationship to study drug. Events captured from baseline to last dose plus 4 days for AEs and plus 30 days for SAEs during the double-blind 12-week period. Data after rescue included.", "timeFrame": "From Baseline to end of Long-term Period (Week 102)"}, {"measure": "Number of Participants With Laboratory Test Results Meeting the Criteria for Laboratory Abnormality", "description": "BUN=blood urea nitrogen; preRX=pretreatment; ULN=upper limit of normal; AST=aspartate aminotransferase; ALT=alanine aminotransferase; ALP=alkaline phosphatase. Phosphorus, inorganic (low): ages 17-65 years, \u22641.8 mg/dL; ages\u226566 years, \u22642.1 mg/dL. Phosphorus, inorganic (high): ages 17-65 years, \u22655.6 mg/dL; ages\u226566 years, \u22655.6 mg/dL. Phosphorus, inorganic (low) \u22641.8 mg/dL if age 17-65 or \u22642.1 mg/dL if age \u226566. Calcium, total (high): \u22651 mg/dL from ULN and \u22650.5 mg/dL from preRx value.", "timeFrame": "Day 1 to Week 102"}, {"measure": "Number of Participants With Changes in Baseline in Electrocardiogram Findings at Week 102 (Last Observation Carried Forward [LOCF])", "description": "12-Lead electrocardiograms (ECGs) were performed at entry into lead-in period Day -7 visit and Week 24/dnd of treatment visit (LOCF) on participants who were supine. ECGs were assessed by the investigator. Baseline was Day -7 for this parameter. Data after rescue included.The Week 102 value is the last observation, regardless of rescue prior to Week 102 if no Week 102 measurement was available.", "timeFrame": "Baseline to Week 102"}, {"measure": "Mean Changes From Baseline in Seated Systolic Blood Pressure", "description": "Blood pressure values were obtained after the participant was seated quietly for 5 minutes; at least 8 hours after the last ingestion of caffeine, alcohol, or nicotine; and in the same arm (right or left) consistently through out the study. Data after rescue were also included. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication.", "timeFrame": "From Baseline to Week 102"}, {"measure": "Mean Changes From Baseline in Seated Diastolic Blood Pressure", "description": "Blood pressure values were obtained after the participant was seated quietly for 5 minutes; at least 8 hours after the last ingestion of caffeine, alcohol, or nicotine; and in the same arm (right or left) consistently through out the study. Data after rescue were also included. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication.", "timeFrame": "From Baseline to Week 102"}, {"measure": "Number of Participants With Orthostatic Hypotension", "description": "Orthostatic hypotension was defined as a decrease from supine to standing blood pressure of \\>20 mm Hg in systolic blood pressure or \\>10 mm Hg in diastolic blood pressure.", "timeFrame": "From Baseline to Week 102"}]}, "eligibilityModule": {"eligibilityCriteria": "Key Inclusion Criteria\n\n* Males and females, 18 to 77 years old, with type 2 diabetes and inadequate glycemic control\n* Participants who have been receiving metformin at a total daily dose \u22651500 mg per day for at least 8 weeks\n* C-peptide \u22651.0 ng/mL\n* Body mass index \u226445.0 kg/m\\^2\n* Serum creatinine level \\<1.50 mg/dL for men or \\<1.40 mg/dL for women.\n\nKey Exclusion Criteria\n\n* Aspartate aminotransferase and/or alanine aminotransferase level \\>3.0 times the upper limit of normal\n* Serum total bilirubin level \\>2 mg/dL\n* Creatinine kinase level \\>3 times upper limit of normal\n* Symptoms of severely uncontrolled diabetes\n* Serum creatinine level \u22651.50 mg/dL for men or \u22651.40 mg/dL for women\n* Currently unstable or serious cardiovascular, renal, hepatic, hematologic, oncologic, endocrine, psychiatric, or rheumatic diseases", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "77 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Bristol-Myers Squibb", "affiliation": "Bristol-Myers Squibb", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Clinical Research Advantage / Desert Clinical Res, Llc", "city": "Tempe", "state": "Arizona", "zip": "85282", "country": "United States", "geoPoint": {"lat": 33.41477, "lon": -111.90931}}, {"facility": "Medical Group Of Encino", "city": "Encino", "state": "California", "zip": "91436", "country": "United States", "geoPoint": {"lat": 34.15917, "lon": -118.50119}}, {"facility": "Valley Research", "city": "Fresno", "state": "California", "zip": "93720", "country": "United States", "geoPoint": {"lat": 36.74773, "lon": -119.77237}}, {"facility": "Randall Shue, D.O.", "city": "Los Angeles", "state": "California", "zip": "90023", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Diabetes Medical Center Of California", "city": "Northridge", "state": "California", "zip": "91325", "country": "United States", "geoPoint": {"lat": 34.22834, "lon": -118.53675}}, {"facility": "Ritchken & First M.D.'S", "city": "San Diego", "state": "California", "zip": "92117", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "Encompass Clinical Research", "city": "Spring Valley", "state": "California", "zip": "91978", "country": "United States", "geoPoint": {"lat": 32.74477, "lon": -116.99892}}, {"facility": "Raikhel, Marina", "city": "Torrance", "state": "California", "zip": "90505", "country": "United States", "geoPoint": {"lat": 33.83585, "lon": -118.34063}}, {"facility": "Express Care Clinical Res", "city": "Colorado Springs", "state": "Colorado", "zip": "80909", "country": "United States", "geoPoint": {"lat": 38.83388, "lon": -104.82136}}, {"facility": "Denver Internal Medicine", "city": "Denver", "state": "Colorado", "zip": "80209", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "New West Physicians", "city": "Golden", "state": "Colorado", "zip": "80401", "country": "United States", "geoPoint": {"lat": 39.75554, "lon": -105.2211}}, {"facility": "Central Florida Clinical Trials, Inc.", "city": "Altamonte Springs", "state": "Florida", "zip": "32701", "country": "United States", "geoPoint": {"lat": 28.66111, "lon": -81.36562}}, {"facility": "Family Care Associates Of Nw Florida", "city": "Chipley", "state": "Florida", "zip": "32428", "country": "United States", "geoPoint": {"lat": 30.78186, "lon": -85.53854}}, {"facility": "Health Partners Research Foundation", "city": "Minneapolis", "state": "Minnesota", "zip": "56440", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "Woodlake Research", "city": "Chesterfield", "state": "Missouri", "zip": "63017", "country": "United States", "geoPoint": {"lat": 38.66311, "lon": -90.57707}}, {"facility": "Nevada Alliance Against Diabetes", "city": "Las Vegas", "state": "Nevada", "zip": "89101", "country": "United States", "geoPoint": {"lat": 36.17497, "lon": -115.13722}}, {"facility": "Diabetes & Endocrinology Consultants, Pc", "city": "Morehead City", "state": "North Carolina", "zip": "28557", "country": "United States", "geoPoint": {"lat": 34.72294, "lon": -76.72604}}, {"facility": "Newark Physician Associates", "city": "Newark", "state": "Ohio", "zip": "43055", "country": "United States", "geoPoint": {"lat": 40.05812, "lon": -82.40126}}, {"facility": "Integris Family Care S. Penn", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73159", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Cumberland Valley Endocrinology Center, Llc", "city": "Carlisle", "state": "Pennsylvania", "zip": "17013", "country": "United States", "geoPoint": {"lat": 40.20148, "lon": -77.18887}}, {"facility": "Banksville Medical Pc", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15216", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Palmetto Clinical Research", "city": "Summerville", "state": "South Carolina", "zip": "29485", "country": "United States", "geoPoint": {"lat": 33.0185, "lon": -80.17565}}, {"facility": "Southeastern Research Assoc", "city": "Taylors", "state": "South Carolina", "zip": "29687", "country": "United States", "geoPoint": {"lat": 34.92039, "lon": -82.29623}}, {"facility": "Texas Center For Drug Development, P.A.", "city": "Houston", "state": "Texas", "zip": "77081", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Diabetes & Glandular Disease Research Associates, Inc.", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "S.A.M. Clinical Research Center", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Optimum Clinical Research", "city": "Salt Lake City", "state": "Utah", "zip": "84102", "country": "United States", "geoPoint": {"lat": 40.76078, "lon": -111.89105}}, {"facility": "Office Of Dr. Gray", "city": "Spokane", "state": "Washington", "zip": "99216", "country": "United States", "geoPoint": {"lat": 47.65966, "lon": -117.42908}}, {"facility": "Local Institution", "city": "Capital Federal", "state": "Buenos Aires", "zip": "1034", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Local Institution", "city": "Capital Federal", "state": "Buenos Aires", "zip": "1429", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Local Institution", "city": "Capital Federal", "state": "Buenos Aires", "zip": "C1056ABJ", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Local Institution", "city": "Capital Federal", "state": "Buenos Aires", "zip": "C1425AGC", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Local Institution", "city": "Ciudad Auton.", "state": "Buenos Aires", "zip": "C1505CWB", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Local Institution", "city": "Ciudad Auton", "state": "Buenos Aires", "zip": "C1408INH", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Local Institution", "city": "Mar Del Plata", "state": "Buenos Aires", "zip": "7600", "country": "Argentina", "geoPoint": {"lat": -38.00228, "lon": -57.55754}}, {"facility": "Local Institution", "city": "Zarate", "state": "Buenos Aires", "zip": "2800", "country": "Argentina", "geoPoint": {"lat": -34.09814, "lon": -59.02858}}, {"facility": "Local Institution", "city": "Villa Carlos Paz", "state": "Cordoba", "zip": "5152", "country": "Argentina", "geoPoint": {"lat": -31.42414, "lon": -64.49778}}, {"facility": "Local Institution", "city": "Buenos Aires", "zip": "1431", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Local Institution", "city": "Cordoba", "zip": "5000", "country": "Argentina", "geoPoint": {"lat": -31.4135, "lon": -64.18105}}, {"facility": "Local Institution", "city": "Fortaleza", "state": "Ceara", "zip": "60021", "country": "Brazil", "geoPoint": {"lat": -3.71722, "lon": -38.54306}}, {"facility": "Local Institution", "city": "Itajuba", "state": "Minas Gerais", "zip": "37502", "country": "Brazil", "geoPoint": {"lat": -22.42556, "lon": -45.45278}}, {"facility": "Local Institution", "city": "Belem", "state": "Para", "zip": "66073", "country": "Brazil", "geoPoint": {"lat": -1.45583, "lon": -48.50444}}, {"facility": "Local Institution", "city": "Caxias Do Sul", "state": "Rio Grande Do Sul", "zip": "95070", "country": "Brazil", "geoPoint": {"lat": -29.16806, "lon": -51.17944}}, {"facility": "Local Institution", "city": "Porto Alegre", "state": "Rio Grande Do Sul", "zip": "90020090", "country": "Brazil", "geoPoint": {"lat": -30.03306, "lon": -51.23}}, {"facility": "Local Institution", "city": "Porto Alegre", "state": "Rio Grande Do Sul", "zip": "90035", "country": "Brazil", "geoPoint": {"lat": -30.03306, "lon": -51.23}}, {"facility": "Local Institution", "city": "Marilia", "state": "Sao Paulo", "zip": "17519", "country": "Brazil", "geoPoint": {"lat": -22.21389, "lon": -49.94583}}, {"facility": "Local Institution", "city": "Rio De Janeiro", "zip": "20211", "country": "Brazil", "geoPoint": {"lat": -22.90278, "lon": -43.2075}}, {"facility": "Local Institution", "city": "Calgary", "state": "Alberta", "zip": "T2R 0X7", "country": "Canada", "geoPoint": {"lat": 51.05011, "lon": -114.08529}}, {"facility": "Local Institution", "city": "Kelowna", "state": "British Columbia", "zip": "V1Y 2H4", "country": "Canada", "geoPoint": {"lat": 49.88307, "lon": -119.48568}}, {"facility": "Local Institution", "city": "Winnipeg", "state": "Manitoba", "zip": "R3E 3P4", "country": "Canada", "geoPoint": {"lat": 49.8844, "lon": -97.14704}}, {"facility": "Local Institution", "city": "Bathurst", "state": "New Brunswick", "zip": "E2A 4X7", "country": "Canada", "geoPoint": {"lat": 47.61814, "lon": -65.65112}}, {"facility": "Local Institution", "city": "Mount Pearl", "state": "Newfoundland and Labrador", "zip": "A1N 1W7", "country": "Canada", "geoPoint": {"lat": 47.51659, "lon": -52.78135}}, {"facility": "Local Institution", "city": "St-John", "state": "Newfoundland and Labrador", "zip": "A1E 2E2", "country": "Canada", "geoPoint": {"lat": 45.2727, "lon": -66.06769}}, {"facility": "Local Institution", "city": "Sarnia", "state": "Ontario", "zip": "N7T 4X3", "country": "Canada", "geoPoint": {"lat": 42.97866, "lon": -82.40407}}, {"facility": "Local Institution", "city": "Thornhill", "state": "Ontario", "zip": "L4J 8L7", "country": "Canada"}, {"facility": "Local Institution", "city": "Toronto", "state": "Ontario", "zip": "M4R 2G4", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "Local Institution", "city": "Toronto", "state": "Ontario", "zip": "M9W 4L6", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "Local Institution", "city": "Charlottetown", "state": "Prince Edward Island", "zip": "C1A 5Y9", "country": "Canada", "geoPoint": {"lat": 46.23899, "lon": -63.13414}}, {"facility": "Local Institution", "city": "Drummondville", "state": "Quebec", "zip": "J2B 7T1", "country": "Canada", "geoPoint": {"lat": 45.88336, "lon": -72.48241}}, {"facility": "Local Institution", "city": "Granby", "state": "Quebec", "zip": "J2G 8Z9", "country": "Canada", "geoPoint": {"lat": 45.40008, "lon": -72.73243}}, {"facility": "Local Institution", "city": "L'Ancienne Lorette", "state": "Quebec", "zip": "G2E 2X1", "country": "Canada", "geoPoint": {"lat": 46.79392, "lon": -71.35191}}, {"facility": "Local Institution", "city": "Mirabel", "state": "Quebec", "zip": "J7J 2K8", "country": "Canada", "geoPoint": {"lat": 45.65008, "lon": -74.08251}}, {"facility": "Local Institution", "city": "St-Leonard", "state": "Quebec", "zip": "H1S 3A9", "country": "Canada", "geoPoint": {"lat": 45.58773, "lon": -73.59501}}, {"facility": "Local Institution", "city": "Saskatoon", "state": "Saskatchewan", "zip": "S7K 3H3", "country": "Canada", "geoPoint": {"lat": 52.13238, "lon": -106.66892}}, {"facility": "Local Institution", "city": "Saskatoon", "state": "Saskatchewan", "zip": "S7K 7H9", "country": "Canada", "geoPoint": {"lat": 52.13238, "lon": -106.66892}}, {"facility": "Local Institution", "city": "Df", "state": "Distrito Federal", "zip": "11800", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "Local Institution", "city": "Guadalajara", "state": "Distrito Federal", "zip": "44670", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Local Institution", "city": "Zapopan", "state": "Distrito Federal", "zip": "45150", "country": "Mexico", "geoPoint": {"lat": 20.72356, "lon": -103.38479}}, {"facility": "Local Institution", "city": "Guadalajara", "state": "Jalisco", "zip": "44650", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Local Institution", "city": "Guadalajara", "state": "Jalisco", "zip": "44670", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Local Institution", "city": "Monterrey", "state": "Nuevo Leon", "zip": "64460", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "Local Institution", "city": "Monterrey", "state": "Nuevo Leon", "zip": "64710", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "Local Institution", "city": "Monterrrey", "state": "Nuevo Leon", "zip": "64700", "country": "Mexico"}, {"facility": "Local Institution", "city": "Tampico", "state": "Tamaulipas", "zip": "89109", "country": "Mexico", "geoPoint": {"lat": 22.26695, "lon": -97.86815}}, {"facility": "Local Institution", "city": "Durango", "zip": "64710", "country": "Mexico", "geoPoint": {"lat": 24.02032, "lon": -104.65756}}]}, "referencesModule": {"references": [{"pmid": "33368935", "type": "DERIVED", "citation": "Shah M, Stolbov L, Yakovleva T, Tang W, Sokolov V, Penland RC, Boulton D, Parkinson J. A model-based approach to investigating the relationship between glucose-insulin dynamics and dapagliflozin treatment effect in patients with type 2 diabetes. Diabetes Obes Metab. 2021 Apr;23(4):991-1000. doi: 10.1111/dom.14305. Epub 2021 Jan 25."}, {"pmid": "31364269", "type": "DERIVED", "citation": "Bailey CJ, Del Prato S, Wei C, Reyner D, Saraiva G. Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes. Diabetes Obes Metab. 2019 Nov;21(11):2564-2569. doi: 10.1111/dom.13841. Epub 2019 Aug 26."}, {"pmid": "27461213", "type": "DERIVED", "citation": "Mellander A, Billger M, Johnsson E, Traff AK, Yoshida S, Johnsson K. Hypersensitivity Events, Including Potentially Hypersensitivity-Related Skin Events, with Dapagliflozin in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis. Clin Drug Investig. 2016 Nov;36(11):925-933. doi: 10.1007/s40261-016-0438-3."}, {"pmid": "26894924", "type": "DERIVED", "citation": "Kohan DE, Fioretto P, Johnsson K, Parikh S, Ptaszynska A, Ying L. The effect of dapagliflozin on renal function in patients with type 2 diabetes. J Nephrol. 2016 Jun;29(3):391-400. doi: 10.1007/s40620-016-0261-1. Epub 2016 Feb 19."}, {"pmid": "23425012", "type": "DERIVED", "citation": "Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013 Feb 20;11:43. doi: 10.1186/1741-7015-11-43. Erratum In: BMC Med. 2013;11:193."}, {"pmid": "20609968", "type": "DERIVED", "citation": "Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010 Jun 26;375(9733):2223-33. doi: 10.1016/S0140-6736(10)60407-2."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Of 915 participants enrolled, 562 completed a qualification period. Of these 562 participants, 546 were randomized and received treatment and 16 were excluded due to adverse events (1), no longer meeting study criteria (7), poor compliance or noncompliance (3), withdrawn consent (4), and lost to follow-up (1).", "groups": [{"id": "FG000", "title": "Placebo + Metformin", "description": "Participants received dapagliflozin-matching placebo once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "FG001", "title": "Dapagliflozin, 2.5 mg + Metformin", "description": "Participants received dapagliflozin, 2.5 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "FG002", "title": "Dapagliflozin, 5 mg + Metformin", "description": "Participants received dapagliflozin, 5 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "FG003", "title": "Dapagliflozin, 10 mg + Metformin", "description": "Participants received dapagliflozin, 10 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}], "periods": [{"title": "Short-term Period (Day 1 to Week 24)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "137"}, {"groupId": "FG001", "numSubjects": "137"}, {"groupId": "FG002", "numSubjects": "137"}, {"groupId": "FG003", "numSubjects": "135"}]}, {"type": "Completed the Period", "achievements": [{"groupId": "FG000", "numSubjects": "119"}, {"groupId": "FG001", "numSubjects": "121"}, {"groupId": "FG002", "numSubjects": "122"}, {"groupId": "FG003", "numSubjects": "121"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "comment": "Completed=entered Long-term Period", "numSubjects": "115"}, {"groupId": "FG001", "comment": "Completed=entered Long-term Period", "numSubjects": "120"}, {"groupId": "FG002", "comment": "Completed=entered Long-term Period", "numSubjects": "122"}, {"groupId": "FG003", "comment": "Completed=entered Long-term Period", "numSubjects": "119"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "22"}, {"groupId": "FG001", "numSubjects": "17"}, {"groupId": "FG002", "numSubjects": "15"}, {"groupId": "FG003", "numSubjects": "16"}]}], "dropWithdraws": [{"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "4"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "3"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "5"}]}, {"type": "Poor compliance/noncompliance", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "No longer meets study criteria", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "2"}]}, {"type": "Administrative reason by author", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "1"}]}]}, {"title": "Long-term Period (Weeks 24 to 102)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "115"}, {"groupId": "FG001", "numSubjects": "120"}, {"groupId": "FG002", "numSubjects": "122"}, {"groupId": "FG003", "numSubjects": "119"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "73"}, {"groupId": "FG001", "numSubjects": "82"}, {"groupId": "FG002", "numSubjects": "89"}, {"groupId": "FG003", "numSubjects": "95"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "42"}, {"groupId": "FG001", "numSubjects": "38"}, {"groupId": "FG002", "numSubjects": "33"}, {"groupId": "FG003", "numSubjects": "24"}]}], "dropWithdraws": [{"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "27"}, {"groupId": "FG001", "numSubjects": "16"}, {"groupId": "FG002", "numSubjects": "17"}, {"groupId": "FG003", "numSubjects": "9"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "2"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "4"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "7"}]}, {"type": "Poor compliance/noncompliance", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "2"}]}, {"type": "Pregnancy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "No longer meets study criteria", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "All randomized participants who received at least 1 dose of study medication", "groups": [{"id": "BG000", "title": "Placebo + Metformin", "description": "Participants received dapagliflozin-matching placebo once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "BG001", "title": "Dapagliflozin, 2.5 mg + Metformin", "description": "Participants received dapagliflozin, 2.5 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "BG002", "title": "Dapagliflozin, 5 mg + Metformin", "description": "Participants received dapagliflozin, 5 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "BG003", "title": "Dapagliflozin, 10 mg + Metformin", "description": "Participants received dapagliflozin, 10 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "137"}, {"groupId": "BG001", "value": "137"}, {"groupId": "BG002", "value": "137"}, {"groupId": "BG003", "value": "135"}, {"groupId": "BG004", "value": "546"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "53.7", "lowerLimit": "30", "upperLimit": "74"}, {"groupId": "BG001", "value": "55.0", "lowerLimit": "30", "upperLimit": "76"}, {"groupId": "BG002", "value": "54.3", "lowerLimit": "33", "upperLimit": "75"}, {"groupId": "BG003", "value": "52.7", "lowerLimit": "29", "upperLimit": "76"}, {"groupId": "BG004", "value": "53.9", "lowerLimit": "29", "upperLimit": "76"}]}]}]}, {"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "Younger than 65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "114"}, {"groupId": "BG001", "value": "116"}, {"groupId": "BG002", "value": "119"}, {"groupId": "BG003", "value": "118"}, {"groupId": "BG004", "value": "467"}]}]}, {"title": "65 to younger than 75 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "23"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "17"}, {"groupId": "BG003", "value": "16"}, {"groupId": "BG004", "value": "75"}]}]}, {"title": "75 years and older", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "4"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "61"}, {"groupId": "BG001", "value": "67"}, {"groupId": "BG002", "value": "68"}, {"groupId": "BG003", "value": "58"}, {"groupId": "BG004", "value": "254"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "76"}, {"groupId": "BG001", "value": "70"}, {"groupId": "BG002", "value": "69"}, {"groupId": "BG003", "value": "77"}, {"groupId": "BG004", "value": "292"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "124"}, {"groupId": "BG001", "value": "117"}, {"groupId": "BG002", "value": "118"}, {"groupId": "BG003", "value": "121"}, {"groupId": "BG004", "value": "480"}]}]}, {"title": "Black/African American", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "4"}, {"groupId": "BG004", "value": "17"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "11"}]}]}, {"title": "Native Hawaiian/Other Pacific Islander", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "1"}]}]}, {"title": "American Indian/Alaskan Native", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "4"}, {"groupId": "BG004", "value": "9"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "5"}, {"groupId": "BG004", "value": "28"}]}]}]}, {"title": "Female Age", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "50 Years and younger", "categories": [{"measurements": [{"groupId": "BG000", "value": "25"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "22"}, {"groupId": "BG003", "value": "22"}, {"groupId": "BG004", "value": "87"}]}]}, {"title": "Older than 50 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "36"}, {"groupId": "BG001", "value": "49"}, {"groupId": "BG002", "value": "46"}, {"groupId": "BG003", "value": "36"}, {"groupId": "BG004", "value": "167"}]}]}]}, {"title": "Body Mass Index", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "<25 kg/m^2", "categories": [{"measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "12"}, {"groupId": "BG003", "value": "12"}, {"groupId": "BG004", "value": "37"}]}]}, {"title": "\u226525 kg/m^2", "categories": [{"measurements": [{"groupId": "BG000", "value": "128"}, {"groupId": "BG001", "value": "133"}, {"groupId": "BG002", "value": "125"}, {"groupId": "BG003", "value": "123"}, {"groupId": "BG004", "value": "509"}]}]}, {"title": "\u226527 kg/m^2", "categories": [{"measurements": [{"groupId": "BG000", "value": "115"}, {"groupId": "BG001", "value": "120"}, {"groupId": "BG002", "value": "111"}, {"groupId": "BG003", "value": "106"}, {"groupId": "BG004", "value": "452"}]}]}, {"title": "\u226530 kg/m^2", "categories": [{"measurements": [{"groupId": "BG000", "value": "79"}, {"groupId": "BG001", "value": "77"}, {"groupId": "BG002", "value": "81"}, {"groupId": "BG003", "value": "75"}, {"groupId": "BG004", "value": "312"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF])", "description": "HbA1c was measured as percent of hemoglobin by a central laboratory. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. HbA1c measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 4, 8, 12, 16, 20, and 24 in the double-blind period.", "populationDescription": "All randomized participants who received study medication and had nonmissing HbA1c values at baseline and Week 24 (LOCF)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percent", "timeFrame": "From Baseline to Week 24", "groups": [{"id": "OG000", "title": "Placebo + Metformin", "description": "Participants received dapagliflozin-matching placebo once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG001", "title": "Dapagliflozin, 2.5 mg + Metformin", "description": "Participants received dapagliflozin, 2.5 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG002", "title": "Dapagliflozin, 5 mg + Metformin", "description": "Participants received dapagliflozin, 5 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG003", "title": "Dapagliflozin, 10 mg + Metformin", "description": "Participants received dapagliflozin, 10 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "134"}, {"groupId": "OG001", "value": "135"}, {"groupId": "OG002", "value": "133"}, {"groupId": "OG003", "value": "132"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.30", "spread": "0.0718"}, {"groupId": "OG001", "value": "-0.67", "spread": "0.0715"}, {"groupId": "OG002", "value": "-0.70", "spread": "0.0722"}, {"groupId": "OG003", "value": "-0.84", "spread": "0.0724"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0002", "pValueComment": "Tested at alpha=0.019, applying the Dunnett adjustment", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.38", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.1014"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Tested at alpha=0.019, applying the Dunnett adjustment", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.41", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.1016"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Tested at alpha=0.019, applying the Dunnett adjustment", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.54", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.1021"}]}, {"type": "SECONDARY", "title": "Adjusted Mean Change From Baseline in Fasting Plasma Glucose at Week 24 (Last Observation Carried Forward [LOCF])", "description": "Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Data after rescue medication was excluded from this analysis. Fasting plasma glucose was measured as milligrams per deciliter (mg/dL) by a central laboratory. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication.", "populationDescription": "All randomized participants who received study medication and who had nonmissing fasting plasma glucose values at baseline and Week 24 (LOCF)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "From Baseline to Week 24", "groups": [{"id": "OG000", "title": "Placebo + Metformin", "description": "Participants received dapagliflozin-matching placebo once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG001", "title": "Dapagliflozin, 2.5 mg + Metformin", "description": "Participants received dapagliflozin, 2.5 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG002", "title": "Dapagliflozin, 5 mg + Metformin", "description": "Participants received dapagliflozin, 5 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG003", "title": "Dapagliflozin, 10 mg + Metformin", "description": "Participants received dapagliflozin, 10 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "136"}, {"groupId": "OG001", "value": "137"}, {"groupId": "OG002", "value": "136"}, {"groupId": "OG003", "value": "132"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-6.0", "spread": "2.673"}, {"groupId": "OG001", "value": "-17.8", "spread": "2.663"}, {"groupId": "OG002", "value": "-21.5", "spread": "2.679"}, {"groupId": "OG003", "value": "-23.5", "spread": "2.721"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0019", "pValueComment": "Statistically significant according to hierarchical testing procedure (p\\<0.05).", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-11.8", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.774"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Statistically significant according to hierarchical testing procedure (p\\<0.05).", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-15.5", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.781"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Statistically significant according to hierarchical testing procedure (p\\<0.05).", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-17.5", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.819"}]}, {"type": "SECONDARY", "title": "Adjusted Mean Change From Baseline in Total Body Weight at Week 24 (Last Observation Carried Forward [LOCF])", "description": "Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Adjusted mean change from baseline in total body weight at Week 24 (or the last postbaseline measurement prior to Week 24 if no Week 24 assessment was available was determined. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Body weight measurements were obtained during the qualification and lead-in periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 of the double-blind period.", "populationDescription": "All randomized participants who received study medication and had nonmissing total body weights at baseline and Week 24 (LOCF)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Kilograms", "timeFrame": "From Baseline to Week 24", "groups": [{"id": "OG000", "title": "Placebo + Metformin", "description": "Participants received dapagliflozin-matching placebo once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG001", "title": "Dapagliflozin, 2.5 mg + Metformin", "description": "Participants received dapagliflozin, 2.5 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG002", "title": "Dapagliflozin, 5 mg + Metformin", "description": "Participants received dapagliflozin, 5 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG003", "title": "Dapagliflozin, 10 mg + Metformin", "description": "Participants received dapagliflozin, 10 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "136"}, {"groupId": "OG001", "value": "137"}, {"groupId": "OG002", "value": "137"}, {"groupId": "OG003", "value": "133"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.89", "spread": "0.2368"}, {"groupId": "OG001", "value": "-2.21", "spread": "0.2357"}, {"groupId": "OG002", "value": "-3.04", "spread": "0.2358"}, {"groupId": "OG003", "value": "-2.86", "spread": "0.2392"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Statistically significant according to hierarchical testing procedure (p\\<0.05).", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.32", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.3344"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Statistically significant according to hierarchical testing procedure (p\\<0.05).", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-2.16", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.3344"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Statistically significant according to hierarchical testing procedure (p\\<0.05).", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.97", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.3365"}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF])", "description": "Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Percent adjusted for baseline HbA1c. Therapeutic glycemic response is defined as HbA1c \\<7.0%. Data after rescue medication was excluded from this analysis. HbA1c was measured as a percent of hemoglobin.", "populationDescription": "All randomized participants who received study medication and were not missing baseline and Week 24 (LOCF) values", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "From Baseline to Week 24", "groups": [{"id": "OG000", "title": "Placebo + Metformin", "description": "Participants received dapagliflozin-matching placebo once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG001", "title": "Dapagliflozin, 2.5 mg + Metformin", "description": "Participants received dapagliflozin, 2.5 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG002", "title": "Dapagliflozin, 5 mg + Metformin", "description": "Participants received dapagliflozin, 5 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG003", "title": "Dapagliflozin, 10 mg + Metformin", "description": "Participants received dapagliflozin, 10 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "134"}, {"groupId": "OG001", "value": "135"}, {"groupId": "OG002", "value": "133"}, {"groupId": "OG003", "value": "132"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "25.9"}, {"groupId": "OG001", "value": "33.0"}, {"groupId": "OG002", "value": "37.5"}, {"groupId": "OG003", "value": "40.6"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1775", "pValueComment": "Statistically significant according to hierarchical testing procedure (p\\<0.05).", "statisticalMethod": "Modified logistic regression", "paramType": "Median Difference (Final Values)", "paramValue": "7.1"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0275", "pValueComment": "Statistically significant according to hierarchical testing procedure (p\\<0.05).", "statisticalMethod": "Modified logistic regression", "paramType": "Mean Difference (Final Values)", "paramValue": "11.7"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0062", "pValueComment": "Statistically significant according to hierarchical testing procedure (p\\<0.05).", "statisticalMethod": "Modified logistic regression", "paramType": "Mean Difference (Final Values)", "paramValue": "14.7"}]}, {"type": "SECONDARY", "title": "Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) in Participants With Baseline HbA1c \u22659.0% at Week 24 (Last Observation Carried Forward [LOCF])", "description": "Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. HbA1c was measured as percent of hemoglobin by a central laboratory. The population included those randomized participants who received treatment and had a baseline HbA1c \\> 9.0%. Data after rescue medication were excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication.", "populationDescription": "All randomized participants who received study medication, who had baseline HbA1c \u22659.0%, and who had nonmissing HbA1c values at Week 24 (LOCF)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percent", "timeFrame": "From Baseline to Week 24", "groups": [{"id": "OG000", "title": "Placebo + Metformin", "description": "Participants received dapagliflozin-matching placebo once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG001", "title": "Dapagliflozin, 2.5 mg + Metformin", "description": "Participants received dapagliflozin, 2.5 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG002", "title": "Dapagliflozin, 5 mg + Metformin", "description": "Participants received dapagliflozin, 5 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG003", "title": "Dapagliflozin, 10 mg + Metformin", "description": "Participants received dapagliflozin, 10 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "34"}, {"groupId": "OG003", "value": "18"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.53", "spread": "0.2345"}, {"groupId": "OG001", "value": "-1.21", "spread": "0.2660"}, {"groupId": "OG002", "value": "-1.37", "spread": "0.1875"}, {"groupId": "OG003", "value": "-1.32", "spread": "0.2595"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValueComment": "Sequential testing procedures were used, and no test was performed for this comparison due to the fact that the previous comparison was not significant.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.68", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.3515"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0068", "pValueComment": "Statistically significant according to hierarchical testing procedure (p\\<0.05).", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.84", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.3022"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0290", "pValueComment": "Statistically significant according to hierarchical testing procedure (p\\<0.05).", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.78", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.3535"}]}, {"type": "SECONDARY", "title": "Adjusted Mean Change From Baseline in Total Body Weight at Week 24 in Participants With Baseline Body Mass Index (BMI) \u226527 kg/m^2 (Last Observation Carried Forward [LOCF])", "description": "Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Adjusted mean change from baseline in total body weight at Week 24 (or the last postbaseline measurement prior to Week 24 if no Week 24 assessment was available was determined.) Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Body weight measurements were obtained during the qualification and lead-in Periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 of the double-blind period.", "populationDescription": "All randomized participants who received study medication, who had baseline BMI \u226527 kg/m\\^2, and who had nonmissing total body weight measurements at Week 24 (LOCF)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Kilograms", "timeFrame": "From Baseline to Week 24", "groups": [{"id": "OG000", "title": "Placebo + Metformin", "description": "Participants received dapagliflozin-matching placebo once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG001", "title": "Dapagliflozin, 2.5 mg + Metformin", "description": "Participants received dapagliflozin, 2.5 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG002", "title": "Dapagliflozin, 5 mg + Metformin", "description": "Participants received dapagliflozin, 5 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG003", "title": "Dapagliflozin, 10 mg + Metformin", "description": "Participants received dapagliflozin, 10 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "114"}, {"groupId": "OG001", "value": "120"}, {"groupId": "OG002", "value": "111"}, {"groupId": "OG003", "value": "108"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.01", "spread": "0.2630"}, {"groupId": "OG001", "value": "-2.39", "spread": "0.2564"}, {"groupId": "OG002", "value": "-3.21", "spread": "0.2661"}, {"groupId": "OG003", "value": "-3.09", "spread": "0.2737"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValueComment": "Sequential testing procedures were used, and no test was performed for this comparison due to the fact that the previous comparison was not significant.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.38", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.3681"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Statistically significant according to hierarchical testing procedure (p\\<0.05).", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-2.19", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.3745"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Statistically significant according to hierarchical testing procedure (p\\<0.05).", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-2.08", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.3791"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Number of Participants With Adverse Events (AEs), Hypoglycemia Events, Related AEs, Death as Outcome, Serious AEs (SAEs), Related SAEs, SAEs Leading to Discontinuation, AEs Leading to Discontinuation, and Hypoglycemia Events Leading to Discontinuation", "description": "AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Related=having certain, probable, possible, or missing relationship to study drug. Events captured from baseline to last dose plus 4 days for AEs and plus 30 days for SAEs during the double-blind 12-week period. Data after rescue included.", "populationDescription": "All randomized participants who received at least 1 dose of blinded study medication", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "From Baseline to end of Long-term Period (Week 102)", "groups": [{"id": "OG000", "title": "Placebo + Metformin", "description": "Participants received dapagliflozin-matching placebo once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG001", "title": "Dapagliflozin, 2.5 mg + Metformin", "description": "Participants received dapagliflozin, 2.5 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG002", "title": "Dapagliflozin, 5 mg + Metformin", "description": "Participants received dapagliflozin, 5 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG003", "title": "Dapagliflozin, 10 mg + Metformin", "description": "Participants received dapagliflozin, 10 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "137"}, {"groupId": "OG001", "value": "137"}, {"groupId": "OG002", "value": "137"}, {"groupId": "OG003", "value": "135"}]}], "classes": [{"title": "At least 1 AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "111"}, {"groupId": "OG002", "value": "111"}, {"groupId": "OG003", "value": "111"}]}]}, {"title": "At least 1 hypoglycemia event", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "7"}, {"groupId": "OG003", "value": "7"}]}]}, {"title": "At least 1 related AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "36"}, {"groupId": "OG002", "value": "33"}, {"groupId": "OG003", "value": "45"}]}]}, {"title": "Deaths", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "At least 1 SAE", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "15"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "14"}]}]}, {"title": "At least 1 related SAE", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "1"}]}]}, {"title": "SAEs leading to discontinuation", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "2"}]}]}, {"title": "AEs leading to discontinuation", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "5"}, {"groupId": "OG003", "value": "6"}]}]}, {"title": "Hypoglycemia events leading to discontinuation", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Number of Participants With Laboratory Test Results Meeting the Criteria for Laboratory Abnormality", "description": "BUN=blood urea nitrogen; preRX=pretreatment; ULN=upper limit of normal; AST=aspartate aminotransferase; ALT=alanine aminotransferase; ALP=alkaline phosphatase. Phosphorus, inorganic (low): ages 17-65 years, \u22641.8 mg/dL; ages\u226566 years, \u22642.1 mg/dL. Phosphorus, inorganic (high): ages 17-65 years, \u22655.6 mg/dL; ages\u226566 years, \u22655.6 mg/dL. Phosphorus, inorganic (low) \u22641.8 mg/dL if age 17-65 or \u22642.1 mg/dL if age \u226566. Calcium, total (high): \u22651 mg/dL from ULN and \u22650.5 mg/dL from preRx value.", "populationDescription": "All randomized participants who received at least 1 dose of study medication and who had nonmissing laboratory values at baseline and Week 102.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Day 1 to Week 102", "groups": [{"id": "OG000", "title": "Placebo + Metformin", "description": "Participants received dapagliflozin-matching placebo once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG001", "title": "Dapagliflozin, 2.5 mg + Metformin", "description": "Participants received dapagliflozin, 2.5 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG002", "title": "Dapagliflozin, 5 mg + Metformin", "description": "Participants received dapagliflozin, 5 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG003", "title": "Dapagliflozin, 10 mg + Metformin", "description": "Participants received dapagliflozin, 10 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "136"}, {"groupId": "OG001", "value": "137"}, {"groupId": "OG002", "value": "136"}, {"groupId": "OG003", "value": "132"}]}], "classes": [{"title": "Hematocrit >55%", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "3"}]}]}, {"title": "Hemoglobin >18 g/dL", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "5"}]}]}, {"title": "BUN \u226560 mg/d or Urea>21.4 mmol/L", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "1"}]}]}, {"title": "Creatinine \u22651.5 preRX creatinine", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "4"}, {"groupId": "OG003", "value": "2"}]}]}, {"title": "Creatinine \u22652.5 mg/dL", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Glucose >350 mg/dL", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "1"}]}]}, {"title": "Creatine kinase >5*ULN", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "3"}, {"groupId": "OG003", "value": "3"}]}]}, {"title": "Creatine kinase >10*ULN", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "1"}]}]}, {"title": "Calcium, total <7.5 mg/dL", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Calcium, total (high)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Potassium, serum \u22656 MEQ/L", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "3"}, {"groupId": "OG003", "value": "2"}]}]}, {"title": "Magnesium, serum <1 mEq/L", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "1"}]}]}, {"title": "Sodium, serum <130 mEq/L", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "3"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Sodium, serum >150 mEq/L", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Phosphorus, inorganic (high)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "5"}]}]}, {"title": "Phosphorus, inorganic (low)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Albumin/creatinine ratio >1800 mg/g", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "3"}, {"groupId": "OG003", "value": "1"}]}]}, {"title": "AST elevation 3*ULN", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "3"}, {"groupId": "OG003", "value": "2"}]}]}, {"title": "ALT elevation 3*ULN", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "2"}]}]}, {"title": "ALT elevation 5*ULN", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Total bilirubin elevation >1.5*ULN", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "4"}]}]}, {"title": "Total bilirubin elevation >2*ULN", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "1"}]}]}, {"title": "ALP elevation >1.5*ULN", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "2"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Number of Participants With Changes in Baseline in Electrocardiogram Findings at Week 102 (Last Observation Carried Forward [LOCF])", "description": "12-Lead electrocardiograms (ECGs) were performed at entry into lead-in period Day -7 visit and Week 24/dnd of treatment visit (LOCF) on participants who were supine. ECGs were assessed by the investigator. Baseline was Day -7 for this parameter. Data after rescue included.The Week 102 value is the last observation, regardless of rescue prior to Week 102 if no Week 102 measurement was available.", "populationDescription": "All randomized participants who received at least 1 dose of study medication and who had nonmissing baseline and Week 102 (LOCF) values", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Baseline to Week 102", "groups": [{"id": "OG000", "title": "Placebo + Metformin", "description": "Participants received dapagliflozin-matching placebo once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG001", "title": "Dapagliflozin, 2.5 mg + Metformin", "description": "Participants received dapagliflozin, 2.5 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG002", "title": "Dapagliflozin, 5 mg + Metformin", "description": "Participants received dapagliflozin, 5 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG003", "title": "Dapagliflozin, 10 mg + Metformin", "description": "Participants received dapagliflozin, 10 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "137"}, {"groupId": "OG001", "value": "137"}, {"groupId": "OG002", "value": "137"}, {"groupId": "OG003", "value": "135"}]}], "classes": [{"title": "Baseline normal/Week 102 normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "74"}, {"groupId": "OG001", "value": "80"}, {"groupId": "OG002", "value": "79"}, {"groupId": "OG003", "value": "82"}]}]}, {"title": "Baseline normal/Week 102 abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "8"}]}]}, {"title": "Baseline normal/Week 102 not reported", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "5"}, {"groupId": "OG003", "value": "9"}]}]}, {"title": "Baseline abnormal/Week 102 normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "20"}, {"groupId": "OG003", "value": "10"}]}]}, {"title": "Baseline abnormal/Week 102 abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "20"}, {"groupId": "OG003", "value": "25"}]}]}, {"title": "Baseline abnormal/Week 102 not reported", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "3"}, {"groupId": "OG003", "value": "1"}]}]}, {"title": "Baseline not reported/Week 102 normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Baseline not reportedl/Week 102 abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Baseline not reported/Week 102 not reported", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Mean Changes From Baseline in Seated Systolic Blood Pressure", "description": "Blood pressure values were obtained after the participant was seated quietly for 5 minutes; at least 8 hours after the last ingestion of caffeine, alcohol, or nicotine; and in the same arm (right or left) consistently through out the study. Data after rescue were also included. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication.", "populationDescription": "All randomized participants who received study medication. n=the number of participants not missing baseline and Week t values.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "From Baseline to Week 102", "groups": [{"id": "OG000", "title": "Placebo + Metformin", "description": "Participants received dapagliflozin-matching placebo once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG001", "title": "Dapagliflozin, 2.5 mg + Metformin", "description": "Participants received dapagliflozin, 2.5 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG002", "title": "Dapagliflozin, 5 mg + Metformin", "description": "Participants received dapagliflozin, 5 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG003", "title": "Dapagliflozin, 10 mg + Metformin", "description": "Participants received dapagliflozin, 10 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "137"}, {"groupId": "OG001", "value": "137"}, {"groupId": "OG002", "value": "137"}, {"groupId": "OG003", "value": "135"}]}], "classes": [{"title": "Week 12 (n=125, 129, 129, 126)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.1", "spread": "1.216"}, {"groupId": "OG001", "value": "-1.6", "spread": "1.380"}, {"groupId": "OG002", "value": "-4.0", "spread": "1.206"}, {"groupId": "OG003", "value": "-3.0", "spread": "1.230"}]}]}, {"title": "Week 24 (n=119, 119, 122, 122)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.2", "spread": "1.229"}, {"groupId": "OG001", "value": "-2.1", "spread": "1.126"}, {"groupId": "OG002", "value": "-4.3", "spread": "1.270"}, {"groupId": "OG003", "value": "-5.1", "spread": "1.329"}]}]}, {"title": "Week 50 (n=105, 116, 111, 113)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.0", "spread": "1.440"}, {"groupId": "OG001", "value": "-0.1", "spread": "1.281"}, {"groupId": "OG002", "value": "-2.1", "spread": "1.314"}, {"groupId": "OG003", "value": "-1.9", "spread": "1.472"}]}]}, {"title": "Week 102 (n=72, 78, 88, 94)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.5", "spread": "1.610"}, {"groupId": "OG001", "value": "0.7", "spread": "1.825"}, {"groupId": "OG002", "value": "-1.1", "spread": "1.412"}, {"groupId": "OG003", "value": "-0.3", "spread": "1.544"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Mean Changes From Baseline in Seated Diastolic Blood Pressure", "description": "Blood pressure values were obtained after the participant was seated quietly for 5 minutes; at least 8 hours after the last ingestion of caffeine, alcohol, or nicotine; and in the same arm (right or left) consistently through out the study. Data after rescue were also included. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication.", "populationDescription": "All randomized participants who received study medication. n=the number of participants not missing baseline and Week t values.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "From Baseline to Week 102", "groups": [{"id": "OG000", "title": "Placebo + Metformin", "description": "Participants received dapagliflozin-matching placebo once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG001", "title": "Dapagliflozin, 2.5 mg + Metformin", "description": "Participants received dapagliflozin, 2.5 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG002", "title": "Dapagliflozin, 5 mg + Metformin", "description": "Participants received dapagliflozin, 5 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG003", "title": "Dapagliflozin, 10 mg + Metformin", "description": "Participants received dapagliflozin, 10 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "137"}, {"groupId": "OG001", "value": "137"}, {"groupId": "OG002", "value": "137"}, {"groupId": "OG003", "value": "135"}]}], "classes": [{"title": "Week 12 (n=125, 129, 129, 126)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.9", "spread": "0.763"}, {"groupId": "OG001", "value": "-1.3", "spread": "0.794"}, {"groupId": "OG002", "value": "-2.3", "spread": "0.714"}, {"groupId": "OG003", "value": "-1.0", "spread": "0.758"}]}]}, {"title": "Week 24 (n=119, 119, 122, 122)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.1", "spread": "0.744"}, {"groupId": "OG001", "value": "-1.8", "spread": "0.863"}, {"groupId": "OG002", "value": "-2.5", "spread": "0.769"}, {"groupId": "OG003", "value": "-1.8", "spread": "0.842"}]}]}, {"title": "Week 50 (n=105, 116, 111, 113)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.1", "spread": "0.861"}, {"groupId": "OG001", "value": "-0.2", "spread": "0.714"}, {"groupId": "OG002", "value": "-2.4", "spread": "0.840"}, {"groupId": "OG003", "value": "-1.2", "spread": "0.921"}]}]}, {"title": "Week 102 (n=72, 78, 88, 94)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.0", "spread": "0.929"}, {"groupId": "OG001", "value": "-0.1", "spread": "0.914"}, {"groupId": "OG002", "value": "-1.5", "spread": "0.861"}, {"groupId": "OG003", "value": "-1.2", "spread": "1.041"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Number of Participants With Orthostatic Hypotension", "description": "Orthostatic hypotension was defined as a decrease from supine to standing blood pressure of \\>20 mm Hg in systolic blood pressure or \\>10 mm Hg in diastolic blood pressure.", "populationDescription": "All randomized participants who received treatment; n=the number of participants who were not missing blood pressure measurements.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "From Baseline to Week 102", "groups": [{"id": "OG000", "title": "Placebo + Metformin", "description": "Participants received dapagliflozin-matching placebo once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG001", "title": "Dapagliflozin, 2.5 mg + Metformin", "description": "Participants received dapagliflozin, 2.5 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG002", "title": "Dapagliflozin, 5 mg + Metformin", "description": "Participants received dapagliflozin, 5 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG003", "title": "Dapagliflozin, 10 mg + Metformin", "description": "Participants received dapagliflozin, 10 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "137"}, {"groupId": "OG001", "value": "137"}, {"groupId": "OG002", "value": "137"}, {"groupId": "OG003", "value": "135"}]}], "classes": [{"title": "Baseline (n=121, 127, 124, 126)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "4"}, {"groupId": "OG003", "value": "4"}]}]}, {"title": "Week 1 (n=126, 121, 119, 114)", "categories": [{"measurements": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "26"}, {"groupId": "OG002", "value": "21"}, {"groupId": "OG003", "value": "19"}]}]}, {"title": "Week 12 (n=123, 128, 127, 125)", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "4"}, {"groupId": "OG003", "value": "5"}]}]}, {"title": "Week 24 (n=116, 114, 118, 121)", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "5"}, {"groupId": "OG003", "value": "3"}]}]}, {"title": "Week 50 (n=103, 115, 109,112)", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "7"}, {"groupId": "OG003", "value": "6"}]}]}, {"title": "Week 102 (n=71, 76, 87, 94)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "3"}]}]}]}, {"type": "SECONDARY", "title": "Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) in Participants With Baseline Body Mass Index (BMI) \u226527 kg/m^2 at Week 24 (Last Observation Carried Forward [LOCF])", "description": "Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Adjusted for baseline HbA1c. HbA1c was measured as percent of hemoglobin by a central laboratory. Data after rescue medication were excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication.", "populationDescription": "All randomized participants who received study medication, who had a BMI \u226527 kg/m\\^2 at baseline, and who had nonmissing HbA1c values at Week 24 (LOCF)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percent", "timeFrame": "From Baseline to Week 24", "groups": [{"id": "OG000", "title": "Placebo + Metformin", "description": "Participants received dapagliflozin-matching placebo once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG001", "title": "Dapagliflozin, 2.5 mg + Metformin", "description": "Participants received dapagliflozin, 2.5 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG002", "title": "Dapagliflozin, 5 mg + Metformin", "description": "Participants received dapagliflozin, 5 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG003", "title": "Dapagliflozin, 10 mg + Metformin", "description": "Participants received dapagliflozin, 10 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "113"}, {"groupId": "OG001", "value": "118"}, {"groupId": "OG002", "value": "109"}, {"groupId": "OG003", "value": "104"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.31", "spread": "0.0792"}, {"groupId": "OG001", "value": "-0.69", "spread": "0.0774"}, {"groupId": "OG002", "value": "-0.71", "spread": "0.0806"}, {"groupId": "OG003", "value": "-0.88", "spread": "0.0826"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValueComment": "Sequential testing procedures were used, and no test was performed for this comparison due to the fact that the previous comparison was not significant.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.38", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.1109"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0004", "pValueComment": "Statistically significant according to hierarchical testing procedure (p\\<0.05).", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.40", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.1129"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Statistically significant according to hierarchical testing procedure (p\\<0.05).", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.57", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.1146"}]}, {"type": "SECONDARY", "title": "Adjusted Mean Change From Baseline in Fasting Plasma Glucose at Week 1 (Last Observation Carried Forward [LOCF])", "description": "Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Data after rescue medication was excluded from this analysis. Fasting plasma glucose was measured by a central laboratory. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication.", "populationDescription": "All randomized participants who received study medication and who had nonmissing fasting plasma glucose values at baseline and Week 1 (LOCF)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "From Baseline to Week 1", "groups": [{"id": "OG000", "title": "Placebo + Metformin", "description": "Participants received dapagliflozin-matching placebo once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG001", "title": "Dapagliflozin, 2.5 mg + Metformin", "description": "Participants received dapagliflozin, 2.5 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG002", "title": "Dapagliflozin, 5 mg + Metformin", "description": "Participants received dapagliflozin, 5 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG003", "title": "Dapagliflozin, 10 mg + Metformin", "description": "Participants received dapagliflozin, 10 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "126"}, {"groupId": "OG001", "value": "120"}, {"groupId": "OG002", "value": "121"}, {"groupId": "OG003", "value": "115"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.2", "spread": "1.934"}, {"groupId": "OG001", "value": "-6.0", "spread": "1.981"}, {"groupId": "OG002", "value": "-12.0", "spread": "1.976"}, {"groupId": "OG003", "value": "-16.5", "spread": "2.030"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValueComment": "Sequential testing procedures were used, and no test was performed for this comparison due to the fact that the previous comparison was not significant.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-7.1", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.769"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Statistically significant according to hierarchical testing procedure (p\\<0.05).", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-13.1", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.762"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Statistically significant according to hierarchical testing procedure (p\\<0.05).", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-17.7", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.808"}]}, {"type": "SECONDARY", "title": "Adjusted Percentage of Participants Achieving Hemoglobin A1c (HbA1C) \u22646.5% at Week 24 (Last Observation Carried Forward [LOCF])", "description": "Secondary endpoints were tested using sequential testing procedure and are presented in hierarchical order. Percent adjusted for baseline HbA1c. Data after rescue medication was excluded from this analysis. HbA1c was measured as a percent of hemoglobin.", "populationDescription": "All randomized participants who received study medication and who had HbA1c values at Baseline and Week 24 (LOCF)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "From Baseline to Week 24", "groups": [{"id": "OG000", "title": "Placebo + Metformin", "description": "Participants received dapagliflozin-matching placebo once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG001", "title": "Dapagliflozin, 2.5 mg + Metformin", "description": "Participants received dapagliflozin, 2.5 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG002", "title": "Dapagliflozin, 5 mg + Metformin", "description": "Participants received dapagliflozin, 5 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}, {"id": "OG003", "title": "Dapagliflozin, 10 mg + Metformin", "description": "Participants received dapagliflozin, 10 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "29"}, {"groupId": "OG002", "value": "18"}, {"groupId": "OG003", "value": "36"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "13.8"}, {"groupId": "OG001", "value": "20.7"}, {"groupId": "OG002", "value": "14.5"}, {"groupId": "OG003", "value": "25.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValueComment": "Sequential testing procedures were used, and no test was performed for this comparison due to the fact that the previous comparison was not significant.", "statisticalMethod": "Modified logistic regression", "paramType": "Mean Difference (Final Values)", "paramValue": "6.9"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.8627", "statisticalMethod": "Modified logistic regression", "paramType": "Mean Difference (Final Values)", "paramValue": "0.7"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0149", "pValueComment": "Statistically significant according to hierarchical testing procedure (p\\<0.05).", "statisticalMethod": "Modified logistic regression", "paramType": "Mean Difference (Final Values)", "paramValue": "11.3"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Placebo + Metformin", "description": "Participants received dapagliflozin-matching placebo once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks", "seriousNumAffected": 14, "seriousNumAtRisk": 137, "otherNumAffected": 84, "otherNumAtRisk": 137}, {"id": "EG001", "title": "Dapagliflozin, 2.5 mg + Metformin", "description": "Participants received dapagliflozin, 2.5 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks", "seriousNumAffected": 15, "seriousNumAtRisk": 137, "otherNumAffected": 87, "otherNumAtRisk": 137}, {"id": "EG002", "title": "Dapagliflozin, 5.0 mg + Metformin", "description": "Participants received dapagliflozin, 5.0 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks", "seriousNumAffected": 9, "seriousNumAtRisk": 137, "otherNumAffected": 77, "otherNumAtRisk": 137}, {"id": "EG003", "title": "Dapagliflozin, 10 mg + Metformin", "description": "Participants received dapagliflozin, 10 mg, once daily plus open-label metformin \u22651500 mg per day for up to 102 weeks", "seriousNumAffected": 14, "seriousNumAtRisk": 135, "otherNumAffected": 83, "otherNumAtRisk": 135}], "seriousEvents": [{"term": "Breast cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 135}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Cervical cord compression", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 135}]}, {"term": "Dengue fever", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Face injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Intervertebral disc protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Loss of consciousness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Malignant melanoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 135}]}, {"term": "Necrobiosis", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Renal cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Rotator cuff syndrome", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 135}]}, {"term": "Spinal cord injury cervical", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Bacteraemia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 135}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Lymphocytic leukaemia", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Angina unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 135}]}, {"term": "Calculus ureteric", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Diverticulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Spinal osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Urethral injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 135}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Coronary artery stenosis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Head injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Inguinal hernia, obstructive", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Myocardial ischaemia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Open fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 135}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 135}]}, {"term": "Rectosigmoid cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 135}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 135}]}, {"term": "Arteriosclerosis coronary artery", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 135}]}, {"term": "Bladder transitional cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Cardiac arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Diabetic gastroparesis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Ischaemic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Lung neoplasm malignant", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Pneumonia aspiration", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Urinary incontinence", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Cardio-respiratory arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Renal failure acute", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 135}]}, {"term": "Thrombocytopenia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Atrioventricular block second degree", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Basal cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 135}]}, {"term": "Breast mass", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 135}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 135}]}, {"term": "Postoperative wound infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 135}]}], "otherEvents": [{"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 13, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 15, "numAtRisk": 135}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 13, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 8, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 7, "numAtRisk": 135}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 19, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 20, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 17, "numAtRisk": 135}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 135}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 10, "numAtRisk": 135}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 12, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 6, "numAtRisk": 135}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 9, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 16, "numAtRisk": 135}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 6, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 135}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 18, "numAtRisk": 135}]}, {"term": "Dyslipidaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 7, "numAtRisk": 135}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 135}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 12, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 16, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 8, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 12, "numAtRisk": 135}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 135}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 135}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 8, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 16, "numAtRisk": 135}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 10, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 135}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 8, "numAtRisk": 135}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 135}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 137}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 137}, {"groupId": "EG003", "numAffected": 7, "numAtRisk": 135}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period \u226460 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication."}, "pointOfContact": {"title": "Bristol-Myers Squibb Study Director", "organization": "Bristol-Myers Squibb", "email": "Clinical.Trials@bms.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Russian Federation"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000529054", "term": "Dapagliflozin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000077203", "term": "Sodium-Glucose Transporter 2 Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M348449", "name": "Dapagliflozin", "asFound": "Body weight", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M1691", "name": "Sodium-Glucose Transporter 2 Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}